Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
Amryt Pharma plc Market Cap
From what 0 stock analysts predict, the share price for Amryt Pharma plc (AMYT) might increase by 27.01% in the next year. This is based on a 12-month average estimation for AMYT. Price targets go from $14.5 to $27. The majority of stock analysts believe AMYT is a sell. Please note analyst price targets are not guaranteed and could be missed completely.
About 0 Wall Street analysts have assigned AMYT 0 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect Amryt Pharma plc to perform worse than the market. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on AMYT. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of AMYT.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Douglas Tsao HC Wainwright & Co. | Neutral | Downgrade | Jan 18, 2023 | |
| Brandon Folkes Cantor Fitzgerald | Neutral | $14.75 | Downgrade | Jan 10, 2023 |
| Edward Nash Canaccord Genuity | Hold | $17 | Downgrade | Jan 10, 2023 |
| Jason McCarthy Maxim Group | Hold | Downgrade | Jan 10, 2023 | |
| Mani Foroohar SVB Leerink | Market Perform | $14.5 | Downgrade | Jan 9, 2023 |
| Edward Nash Canaccord Genuity | Buy | $19 | Assumes | Sep 6, 2022 |
| Mani Foroohar SVB Leerink | Outperform | $19 | Maintains | Jun 24, 2022 |
| Mani Foroohar SVB Leerink | Outperform | $18 | Maintains | May 5, 2022 |
| Douglas Tsao HC Wainwright & Co. | Buy | $18 | Maintains | Mar 10, 2022 |
| Mani Foroohar SVB Leerink | Outperform | $10 | Maintains | Mar 10, 2022 |
| Mani Foroohar SVB Leerink | Outperform | $19 | Maintains | Nov 23, 2021 |
JonesTrading | Buy | Initiates | Oct 4, 2021 | |
SVB Leerink | Outperform | Initiates | Aug 19, 2021 | |
HC Wainwright & Co. | Buy | Initiates | Jul 27, 2021 | |
Maxim Group | Buy | Initiates | Mar 31, 2021 | |
SVB Leerink | Outperform | Initiates | Feb 16, 2021 | |
Canaccord Genuity | Buy | Initiates | Jul 20, 2020 | |
Cantor Fitzgerald | Overweight | Initiates | Jul 9, 2020 |
When did it IPO
2020
Staff Count
289
Country
United States
Sector/Industry
Healthcare/Drug Manufacturers—Specialty & Generic
CEO
Dr. Joseph A. Wiley
Market Cap
$942.8M
In 2023, AMYT generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that AMYT's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Thu, 09 Nov 2023
Sentiment - POSITIVE
Source - Proactive Investors
Summary - Poolbeg Pharma PLC has appointed former Amryt Pharma executives to enhance its management, aiming to advance clinical assets, with Chairman Cathal Friel leading the strategy.
Why It Matters - The appointment of experienced executives from Amryt Pharma signals Poolbeg Pharma's intent to enhance its clinical pipeline and strategic direction, potentially increasing investor confidence and future valuations.
Wed, 12 Apr 2023
Sentiment - NEUTRAL
Source - PRNewsWire
Summary - Chiesi Farmaceutici has completed the acquisition of Amryt Pharma, enhancing its portfolio in rare disease treatments. Amryt is a commercial-stage biopharmaceutical company.
Why It Matters - Chiesi's acquisition of Amryt enhances its portfolio in rare diseases, potentially boosting revenue and market position, which can positively impact stock performance and investor sentiment.
Tue, 11 Apr 2023
Sentiment - POSITIVE
Source - Seeking Alpha
Summary - Amryt Pharma is set to be acquired for $14.50 per share, with a contingent value right featuring two milestones of $1 and $1.50. The stock is currently trading at $14.69.
Why It Matters - Amryt Pharma's acquisition price is close to its current trading value, indicating market confidence in the deal. The contingent value rights offer potential upside, enhancing investor interest.
Wed, 22 Mar 2023
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Amryt Pharma shareholders have approved the acquisition of the company by Chiesi Farmaceutici.
Why It Matters - The approval of Amryt Pharma's acquisition by Chiesi Farmaceutici signals potential growth opportunities, strategic alignment, and impacts on share valuation, affecting investor sentiment and stock performance.
Mon, 27 Feb 2023
Sentiment - NEUTRAL
Source - Business Wire
Summary - Halper Sadeh LLC is investigating the fairness of Chiesi Farmaceutici's proposed acquisition of Amryt Pharma for $14.50 per ADS, plus potential additional payments related to Filsuvez®.
Why It Matters - Concerns over the fairness of Amryt Pharma's sale could impact stock valuation and shareholder sentiment, influencing trading and investment decisions in the biotech sector.
Fri, 24 Feb 2023
Sentiment - NEUTRAL
Source - Business Wire
Summary - Amryt Pharma Plc is proposed to be sold to Chiesi Farmaceutici S.p.A. for $14.50 per share in cash, plus a Contingent Value Right of up to $2, prompting an investigation by KSF.
Why It Matters - The investigation into Amryt Pharma's sale may signal potential risks or changes in the deal, affecting stock valuation and investor sentiment regarding the acquisition's viability.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
